Showing results (111-120 of 137) with videos related to
Sort By:
Pageof 14
Journal of the American Academy of Dermatology|September 17, 2022
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trialBruce Strober, Diamant Thaçi, Howard Sofen, et al.The Journal of Dermatological Treatment|June 30, 2024
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trialsNeil J Korman, Richard B Warren, Jerry Bagel, et al.Journal of the American Academy of Dermatology|July 12, 2022
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trialApril W Armstrong, Melinda Gooderham, Richard B Warren, et al.Immunotherapy|May 8, 2023
Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-1 study): a plain language summaryApril W Armstrong, Melinda Gooderham, Richard B Warren, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|March 7, 2024
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2)Bruce Strober, Andrew Blauvelt, Richard B Warren, et al.The Journal of Biological Chemistry|July 31, 2020
Hepatocyte expression of the micropeptide adropin regulates the liver fasting response and is enhanced by caloric restrictionSubhashis Banerjee, Sarbani Ghoshal, Joseph R Stevens, et al.Nature|March 31, 2012
Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonistsLaura A Solt, Yongjun Wang, Subhashis Banerjee, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|March 6, 2025
Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trialsApril W Armstrong, Mark Lebwohl, Richard B Warren, et al.Rheumatology and Therapy|March 3, 2023
Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid ArthritisPaul Emery, Yoshiya Tanaka, Vivian P Bykerk, et al.Biophysical Journal|January 26, 2017
Molecular-Scale Biophysical Modulation of an Endothelial Membrane by Oxidized PhospholipidsManuela A A Ayee, Elizabeth LeMaster, Tzu Pin Shentu, et al.Pageof 14